GEMMABio focuses on accelerating gene therapy research and product development to bring advanced therapies for rare diseases from bench to bedside more quickly and affordably. The company provides research and product development functions and is led by gene therapy pioneer Dr. Jim Wilson and a team formerly working in academia. Since its launch on October 1, 2024, GEMMABio has several active programs and has announced a collaboration with Fiocruz in Brazil. The company says it is building momentum and is actively seeking strategic partners to support development and global access. Financially, GEMMABio completed a $34 million seed funding round to support operational expansion and its gene therapy programs. The company emphasizes a patient-centered approach and intends to use the new capital to accelerate development and delivery of therapies worldwide.

Total raised

$34M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2024